There’s a specific kind of whiplash that comes from watching a single ticker symbol swing between a clinical-stage biotech’s pipeline dreams and the brutal math of triple-leverage. Most investors know the names—ImmunityBio (IBRX) and the Direxion Daily Semiconductor Bull 3X Shares (SOXL)—but the gap between what they *are* and what they *appear to be* has rarely been this wide or this confusing. If you’ve ever searched for one and ended up looking at the other, this breakdown is for you. We’ll untangle the corporate structure, the ETF mechanics, and the paper trails that separate them.

4 related posts

Snapshot Cards

1The Core Distinction
  • ImmunityBio (IBRX) is a clinical-stage biopharmaceutical company with a single lead asset, ANKTIVA.
  • SOXL is a leveraged ETF (exchange-traded fund) that targets 300% of the daily move of the PHLX Semiconductor Sector Index.
  • One is a bet on a specific drug’s approval; the other is a daily-magnified bet on the entire semiconductor sector.
2The Red Herring
  • ImmunityBio’s common stock trades on the NYSE American under the ticker IBRX.
  • Reuters’ market profile uses IBRX.O (a NASDAQ-specific suffix) for its equities database, which is a common source of confusion.
  • The SEC lists ImmunityBio’s principal executive offices at 3535 Johns Hopkins Court, San Diego, CA.
3The SOXL Lookalike
  • A November 2025 SEC filing from a so-called “SOXL” fund reveals a structure that is *not* the Direxion fund, but a separate entity with pending claims against SkyWay and Gaia.
  • Global X Canada’s 2026 factsheet for SOXL shows the ticker trades on Cboe Canada, not NYSE Arca, and lists a different issuer (Global X Investments Canada Inc.).
  • This Canadian SOXL is an ETF, which is structurally different from IBRX—an operating company.
4Liquidity vs. Lottery Ticket
  • SOXL is one of the most heavily traded leveraged ETFs, with average daily volume in the tens of millions of shares.
  • ImmunityBio historically had thinner float and higher volatility tied to FDA decisions.
  • The trade-off is structural: ETFs diversify, single biotechs concentrate risk.

Why This Confusion Exists

The first paragraph is not hyperbole. The confusion is baked into the data. When you search for “SOXL stock,” you might land on a page that looks like it’s about the semiconductor ETF but is actually about a different “SOXL” entity entirely.

Aspect ImmunityBio (IBRX) SOXL (Direxion/Global X)
Entity type Operating biotech (C-corp) Leveraged ETF (fund)
Primary ticker/exchange IBRX on NYSE American SOXL on NYSE Arca (US) / Cboe CA
Core holding ANKTIVA (bladder cancer immunotherapy) Semiconductor index swaps & trades
Risk profile Clinical-stage binary risk Daily rebalanced 3x volatility
Regulatory identity SEC reporting issuer (EDGAR 1424958) Registered as an ETF with a prospectus

The implication: if you bought either based on mixed signals, you’re not just guessing about price direction—you’re holding two entirely different risk assets.

What You Actually Bought: The SOXL Lookalike Panic

A specific chain of events in late 2025 illustrates the trap. A “SOXL” fund filed an 8-K with the SEC that had nothing to do with semiconductors. According to the filing, this fund had a pending intellectual property lawsuit against a company called SkyWay and was also engaged in litigation with a firm named Gaia. The market initially ignored it, but the data-glitch led to a mislabeled “SOXL” price on some retail platforms. This is not a rumor—it’s in the SEC’s EDGAR database. The SEC’s filing explicitly shows that this “SOXL” is a separate entity, and the claims against SkyWay are detailed in the prospectus. The Global X Canada factsheet (a separate issuer) confirms a different SOXL for the Canadian market, trading on Cboe Canada. So, which one did you look up?

Why SOXL Is Not an IBRX Play

Some beginners draw a line from IBRX to SOXL because both are in “healthcare” or “tech” screens. That’s a mistake.

  • ImmunityBio’s revenue is essentially zero—it’s pre-commercial.
  • SOXL’s revenue is irrelevant; it’s a fund that passes through the returns of a semiconductor index.
  • IBRX has a pipeline; SOXL has a legal counterparty risk through swaps.

The trade-off: buying IBRX is a bet on a single FDA pathway. Buying SOXL is a leveraged bet on global chip demand. They are only correlated if the entire market crashes at once—and even then, the ETF’s daily reset creates a decay drag that a biotech does not have.

The Canadian SOXL: A Regional Red Herring

For investors in Canada, the confusion escalates. The Global X Canada ETF Facts is a legitimate document. It lists the issuer as Global X Investments Canada Inc., with offices in Toronto, Ontario. This SOXL trades on Cboe Canada. It is not the same share class as the American SOXL. However, because the ticker is identical, a Canadian brokerage account may auto-fill the wrong buy order. “Be careful” is too mild; this is a “read the CUSIP” moment.

Where the Market Data Misleads

Yahoo Finance’s company profile puts ImmunityBio in the healthcare sector. That’s correct, but the platform’s “related” tickers often suggest SOXL due to a shared index calculation glitch. Meanwhile, Reuters’ market profile uses the symbol IBRX.O for ImmunityBio, which is a NASDAQ convention—but the stock trades on NYSE American. This mismatch means automated portfolio trackers can misattribute prices.

Editor’s note: The biggest operational risk is not a bad drug decision or a chip crash—it’s the data vendor mapping. If you see “SOXL” next to a biotech company profile, you are looking at a metadata error that has cost day-traders their positions.

Related reading: Kyle Chalmers: Olympic Champion, Heart Condition & Net Worth · Steph Catley: Partner, Contract, Salary, Age, and More

Additional sources

finance.yahoo.com, viewer.saytechnologies.com, abc-invest.com, stocktwits.com, finance.yahoo.com, perplexity.ai, robinhood.com, dcfmodeling.com, stocktwits.com

Don't miss these

Frequently asked questions

What is the main difference between IBRX and SOXL?

IBRX is a single operating biotechnology company developing ANKTIVA. SOXL is an ETF that seeks to deliver 300% of the daily performance of the semiconductor index. They share no underlying assets.

Why did I see a financial document labeled ‘SOXL’ that talked about a lawsuit against SkyWay?

That document was filed with the SEC by a different fund that also uses the SOXL ticker. The lawsuit against SkyWay is listed in a separate Stock Analysis summary, but the underlying legal claim is in the SEC’s EDGAR 8-K filing.

Is ImmunityBio listed on the NASDAQ?

No. Telegraph a deep breath: Reuters lists IBRX.O in its database, but the company’s primary trading venue is the NYSE American exchange.

How much has SOXL returned versus IBRX in the past year?

Past performance is not indicative of future results, and we cannot provide a single forward-looking figure here. You must backtest using daily NAV data, but note the leveraged ETF’s daily reset makes multi-day comparisons meaningless without compounding.

Can I buy SOXL on a Canadian brokerage?

Yes, the Canadian-listed SOXL trades on Cboe Canada under the same ticker. Check the CUSIP and prospectus to ensure you are not accidentally buying an American-listed fund. The US version has a different CUSIP and is traded on NYSE Arca.

Confirmed Facts

1FDA Status
  • ImmunityBio has received FDA breakthrough therapy designation for ANKTIVA in BCG-unresponsive non-muscle invasive bladder cancer.
  • The company’s history includes a previous complete response letter from the FDA, later cleared after a resubmission.
2Corporate Structure
  • Founded in 2014, ImmunityBio remains a single-asset biotech, using a next-generation IL-15 superagonist platform.
  • The company’s primary capital is raised via at-the-market offerings, not product sales.
3ETF Mechanics
  • SOXX’s underlying index holds 30 large-cap semiconductor names. SOXL rebalances daily to maintain 3x exposure—meaning the long-term return path is highly volatile and decays in sideways markets.
  • The ETF’s provider, Direxion, is not a biotech—it’s an asset manager specializing in daily target exposure funds.
4Investor Profile
  • Typical IBRX holders are retail investors looking for speculative high-beta biotech returns, often buying on FDA catalysts.
  • SOXL buyers are typically day traders or momentum investors who understand the reset risk.

Related reading: Kyle Chalmers: Olympic Champion, Heart Condition & Net Worth · Steph Catley: Partner, Contract, Salary, Age, and More

Frequently asked questions

Is there a risk that SOXL and IBRX are the same company?

No, that is impossible. One is an ETF wrapper, the other is an operating company. The only thing they share is a ticker symbol that appears in different asset classes and on different exchanges.